PAncreatic Disease Cohort of TOuLouse

Study Overview
=================
Brief Summary
-----------------
This study is a prospective cohort dedicated to pancreatic diseases excluding cancer. The aim is to develop positive or differential diagnostic tools between benign potentially malignant or malignant pancreatic pathologies. During this study the investigators collect data and biological samples to support research project.

Detailed Description
-----------------
This collection focuses on pathology of the pancreas requiring specific investigations or management for diagnosis or treatment. Pancreatic pathologies can be classified as malignant, potentially malignant or benign tumors. These can be solid or cystic. There is an inflammatory attack on the pancreas, generating acute pancreatitis in the acute period, if the inflammatory manifestations persist, chronic pancreatitis will develop. Some lesions may be at risk of malignancy during their evolution, it is therefore necessary to improve the performance of monitoring and diagnostic tools in order to adapt the management of patients.

Official Title
-----------------
PAncreatic Disease Cohort of TOuLouse

Conditions
-----------------
Pancreatic Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with inflammatory or cystic exocrine pancreatic pathology Patient able to read and understand the information leaflet Patients who have agreed to participate in the study and have signed the free and informed consent Patients affiliated to a social security system (including AME) Exclusion Criteria: Patient with pancreatic cancer pathology Patients with active cancer, whatever the origin Pregnant or breastfeeding patients Patients under legal protection, guardianship or trusteeship

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic tools | To develop positive or differential diagnostic tools between benign potentially malignant or malignant pancreatic pathologies | 3 years after the first inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| New targets | To identify new screening targets | 3 years after the first inclusion | 
| Improvement of management | To improve the management of cystic lesions or Chronic pancreatitis on the decision of therapeutic management | 3 years after the first inclusion | 
| Microbiota | Study of the microbiota of pancreatic diseases | 3 years after the first inclusion | 
| Clinical data access | To make available to the scientific community quality material with associated clinical data also of quality | 3 years after the first inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pancreatic cyst, Acute pancreatitis, chronic pancreatitis, Intra Pancreatic Mucinous Neoplasia, diagnosis